Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2018 Mar 1;24(7):1463–1470. doi: 10.1016/j.bbmt.2018.02.012

Figure 4.

Figure 4

Overall survival – all cause mortality, for study (Carlecortemcel-L) (84.2%) and DUCBT (74.6%) treated patients: Odds ratio 0.50, 95% CI (0.26,0.95); p = 0.035